{"gene":"PRPS2","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2014,"finding":"PRPS2 is a rate-limiting enzyme for nucleotide biosynthesis that is specifically upregulated at the translational level downstream of Myc activation via a specialized cis-regulatory element in the PRPS2 5' UTR controlled by the translation initiation factor eIF4E. A Prps2 knockout mouse demonstrated that this Myc→eIF4E→PRPS2 axis is required for Myc-driven tumorigenesis, coupling protein synthesis (via eIF4E) and nucleotide biosynthesis (via PRPS2) in a single anabolic circuit.","method":"5' UTR reporter assays, Prps2 knockout mouse, Myc-transformed cell lines, metabolic assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — genetic knockout mouse with defined phenotype, mechanistic 5'UTR reporter assays, multiple orthogonal methods in a single highly-cited study","pmids":["24855946"],"is_preprint":false},{"year":2008,"finding":"PRPS2 is a direct transcriptional target of C-MYC and is rate-limiting for dNTP metabolism in melanoma cells. shRNA-mediated knockdown of PRPS2 reduced dNTP pools and retarded cell cycle progression similarly to C-MYC depletion; conversely, PRPS2 overexpression (together with TS and IMPDH2) delayed proliferative arrest caused by C-MYC inhibition. ChIP confirmed direct C-MYC binding to the PRPS2 gene.","method":"shRNA knockdown, cDNA overexpression, dNTP pool measurements, ChIP, cell cycle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, KD, OE, metabolite measurement) with defined phenotypic readouts","pmids":["18677108"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of human PRPS2 at 3.08 Å resolution revealed that hPRPS2 hexamers stack into polymers in the presence of the allosteric/competitive inhibitor ADP. The binding modes of ADP at the canonical allosteric site and at the catalytic active site were determined. A point mutation disrupting inter-hexamer contacts prevents hPRPS2 polymerization and results in significantly reduced catalytic activity, demonstrating that polymer formation regulates enzymatic activity. The regulation of hPRPS2 polymers is distinct from that of E. coli PRPS polymers.","method":"Cryo-EM structure determination (3.08 Å), site-directed mutagenesis, in vitro polymerization and activity assays","journal":"Cell & bioscience","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution cryo-EM structure combined with mutagenesis and activity assays","pmids":["37248548"],"is_preprint":false},{"year":2022,"finding":"PRPS2 mutations found exclusively in relapsed childhood ALL drive thiopurine resistance by influencing PRPS1/PRPS2 hexamer stability. The 3-amino acid insertion V103-G104-E105 in PRPS2 causes steric clash at the hexamer interface, reducing enzyme activity. Functional PRPS2 mutations reduce ADP/GDP feedback inhibition of PRPS enzyme activity, enhancing purine metabolic flux and thiopurine resistance, demonstrated in cell lines and xenograft models.","method":"Ultra-deep sequencing, in vitro PRPS2 enzyme activity assays, ADP/GDP feedback inhibition assays, UPLC-MS/MS metabolite profiling, xenograft mouse models","journal":"Blood science (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro enzyme activity assays, metabolomics, and in vivo xenograft validation with mechanistic structural explanation","pmids":["36742181"],"is_preprint":false},{"year":2025,"finding":"PRPS2 uses four non-conserved key residues to bypass typical ADP/GDP allosteric feedback inhibition, enabling sustained excess ATP production. Additionally, PRPS2 directly interacts with and stabilizes methionine adenosyltransferase 2A (MAT2A) through protein-protein interaction, stimulating SAM synthesis which feeds the WTAP/METTL3/METTL14 methyltransferase complex for RNA m6A methylation, thereby promoting lung tumorigenesis. This reveals both enzyme-dependent (ATP production) and enzyme-independent (MAT2A stabilization) oncogenic functions of PRPS2.","method":"Co-immunoprecipitation, protein stability assays, mutational analysis of allosteric sites, m6A methylation assays, in vitro and in vivo tumorigenesis assays, MAT2A interaction studies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (Co-IP, mutagenesis, methylation assays, in vivo tumor models) establishing both enzyme-dependent and independent mechanisms","pmids":["40295500"],"is_preprint":false},{"year":2019,"finding":"PRPS2 promotes migration and invasion of colorectal cancer cells by regulating the activity of matrix metalloproteinase 9 (MMP-9) and the expression of E-cadherin. Upregulation of PRPS2 in metastatic CRC cells is induced by the MYC proto-oncogene.","method":"PRM-based targeted proteomics, migration/invasion assays, MMP-9 activity assays, Western blot, siRNA knockdown","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional assays with defined molecular outputs (MMP-9, E-cadherin) from a single lab","pmids":["30908912"],"is_preprint":false},{"year":2015,"finding":"PRPS2 overexpression in TM4 Sertoli cells inhibits apoptosis and promotes cell cycle transition via the p53/Bcl-2/caspase-9/caspase-3/caspase-6/caspase-7 signaling pathway, as demonstrated by lentiviral gain- and loss-of-function experiments with flow cytometry readouts.","method":"Lentiviral overexpression and knockdown, flow cytometry (apoptosis, cell cycle), Western blot for apoptosis pathway proteins","journal":"The Journal of urology","confidence":"Medium","confidence_rationale":"Tier 2–3 — defined apoptosis pathway placement via gain/loss of function with multiple apoptosis markers, single lab","pmids":["26004865"],"is_preprint":false},{"year":2020,"finding":"PRPS2 depletion in mouse testes causes hypospermatogenesis and accelerated spermatogenic cell apoptosis. E2F1 transcription factor was identified as a target gene regulated by PRPS2, with E2F1 acting through the P53/Bcl-xl/Bcl-2/Caspase 6/Caspase 9 apoptosis pathway. In vivo knockdown of PRPS2 in mouse testes confirmed the hypospermatogenesis phenotype.","method":"In vivo testicular PRPS2 knockdown in mice, spermatogenic cell apoptosis quantification, E2F1 target gene analysis, apoptosis pathway protein assays","journal":"Asian journal of andrology","confidence":"Medium","confidence_rationale":"Tier 2–3 — in vivo knockdown with defined phenotype and identification of downstream transcription factor, single lab","pmids":["31736475"],"is_preprint":false},{"year":2021,"finding":"PRPS2 silencing enhances cisplatin sensitivity in NSCLC cells. PRPS2 is enriched in exosomes secreted by NSCLC cells, and exosomal PRPS2 mediates M2 macrophage polarization, which in turn promotes cisplatin resistance in NSCLC cells.","method":"siRNA knockdown, exosome isolation by ultracentrifugation, MTT and colony formation assays, ELISA, caspase-3 activity assay, macrophage polarization assays","journal":"Immunological investigations","confidence":"Medium","confidence_rationale":"Tier 3 — functional assays with exosome mechanistic link, single lab, no structural or biochemical reconstitution","pmids":["34251965"],"is_preprint":false},{"year":2024,"finding":"PRPS2 regulates chemotaxis of tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) in lung cancer by controlling CCL2 expression. In vivo LLC tumor models showed that PRPS2 knockdown reduced TAM/MDSC infiltration and increased CD4+/CD8+ T cell percentages; CCL2 antibody treatment reversed the pro-tumorigenic phenotype induced by PRPS2 overexpression.","method":"Lentiviral stable cell lines, in vivo mouse tumor models, FACS, in vitro transwell chemotaxis assay, qPCR, Western blot, ELISA","journal":"Thoracic cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 — in vivo tumor model with multiple immune cell readouts; CCL2 identified as intermediate; single lab","pmids":["38952044"],"is_preprint":false},{"year":2024,"finding":"Host PRPS2 directly interacts with Avian Reovirus non-structural protein p17, as validated by yeast two-hybrid, coimmunoprecipitation, GST-pulldown, and laser confocal microscopy. The C-terminal region of PRPS2 is responsible for binding p17. ARV infection upregulates PRPS2, and PRPS2 overexpression increases ARV replication while knockdown decreases it, with cellular apoptosis implicated as a mechanism.","method":"Yeast two-hybrid, coimmunoprecipitation, GST-pulldown, laser confocal microscopy, overexpression and knockdown in avian cells","journal":"Poultry science","confidence":"Medium","confidence_rationale":"Tier 2–3 — interaction validated by multiple orthogonal methods; functional consequence shown by gain/loss of function; avian host context","pmids":["39631276"],"is_preprint":false},{"year":2025,"finding":"Genetic inactivation of the PRPS2 isozyme (but not PRPS1) in MYC-driven lymphoma cells leads to elevated NADPH levels and reductive stress-mediated cell death, identifying PRPS2 as a primary regulator of redox homeostasis in Myc-overexpressing B cell lymphomas. MYC overexpression rapidly stimulates PRPS2-dependent nucleotide synthesis and modulates the pentose phosphate pathway and mitochondrial respiration to shift redox equilibrium toward a more oxidative state. Pharmacological targeting of PRPS1 versus PRPS2 elicits opposing sensitivity or resistance to thioredoxin/glutathione network-targeting chemotherapeutics.","method":"Genetic isozyme-specific inactivation (PRPS2 KO vs PRPS1 KO), NADPH measurements, pharmacological screen, redox assays in MYC-overexpressing B cell lymphoma cells","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — isozyme-specific genetic inactivation with metabolic readouts; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.01.08.632009"],"is_preprint":true},{"year":2024,"finding":"PRPS2 operates as part of a large mammalian PRPS enzyme complex together with PRPS1, PRPS3 (testis-restricted), and two non-enzymatic associated proteins (PRPSAP1, PRPSAP2). PRPS2, PRPSAP1, and PRPSAP2 are required for proper PRPS1 assembly; cells lacking all three render PRPS1 into aberrant homo-oligomeric assemblies with diminished metabolic flux and impaired proliferative capacity. Preferential interactions between complex subunits were defined using isogenic fibroblast clones in all viable individual or combinatorial assembly states. Translational control mechanisms enable fine-tuned regulation of PRPS complex assembly.","method":"Isogenic fibroblast knockout clones (individual and combinatorial), co-fractionation, affinity purification, metabolic flux analysis, proliferation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — comprehensive combinatorial genetic approach with metabolic and proliferative readouts; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2024.10.01.616059"],"is_preprint":true},{"year":1989,"finding":"The PRPS2 gene was localized to the X chromosome at a different region than PRPS1, specifically Xpter-q21, using Southern blot analysis of human-mouse somatic cell hybrids and flow-sorted human chromosomes, demonstrating that PRPS1 and PRPS2 are encoded by distinct, separated loci on the X chromosome.","method":"Southern blot analysis of somatic cell hybrids, flow-sorted chromosome hybridization","journal":"Somatic cell and molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — definitive chromosomal mapping by molecular genetics","pmids":["2536962"],"is_preprint":false},{"year":1992,"finding":"The PRPS2 gene promoter region is GC-rich, contains a TATA-like sequence, four Sp1 binding sites, and a homopyrimidine stretch, with transcription initiation sites 90 nucleotides upstream from the ATG codon. CAT/promoter fusion assays in four cell lines demonstrated that a 1.1 kb PRPS2 5'-flanking region possesses promoter activity correlated with steady-state PRPS2 mRNA levels, suggesting this region drives cell-differential expression.","method":"Promoter cloning, sequencing, CAT/promoter fusion reporter assays in multiple cell lines","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter activity demonstrated by reporter assays in multiple cell lines","pmids":["1314091"],"is_preprint":false},{"year":2026,"finding":"Pseudoginsenoside F11 (PF11) inhibits PRPS2 transcription by binding to the transcription factor YBX1, enhancing its affinity for the PRPS2 promoter and enabling displacement of the transcriptional activator c-Myc. YBX1 then recruits the NuRD corepressor complex to the PRPS2 promoter, leading to transcriptional repression of PRPS2, suppression of TNBC stemness, and reduction of pulmonary metastasis in murine models.","method":"PRPS2-promoter luciferase reporter assay, biotin-conjugated pull-down, ChIP, YBX1 knockdown/overexpression, in vitro mammosphere assay, murine pulmonary metastasis model","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2–3 — mechanistic promoter studies with ChIP and pull-down; in vivo validation; single lab","pmids":["41855762"],"is_preprint":false}],"current_model":"PRPS2 is an X-linked phosphoribosyl pyrophosphate synthetase that catalyzes the rate-limiting step of nucleotide biosynthesis; it forms hexamers that stack into higher-order polymers (whose structure and ADP-inhibited state are defined at atomic resolution), assembles into a large heteromeric complex with PRPS1, PRPSAP1, and PRPSAP2, and is selectively upregulated at the translational level by the Myc→eIF4E axis via a specialized 5'UTR element; beyond its enzymatic role in ATP/PRPP production, PRPS2 independently stabilizes MAT2A to drive SAM synthesis and RNA m6A methylation, regulates redox homeostasis (NADPH/NADP+ balance) in MYC-driven lymphoma, modulates apoptosis through p53/Bcl-2/caspase cascades and E2F1, and promotes tumor invasion via MMP-9/E-cadherin regulation and immune evasion via CCL2-mediated macrophage/MDSC recruitment."},"narrative":{"teleology":[{"year":1989,"claim":"Mapping PRPS2 to the X chromosome at a locus distinct from PRPS1 established that two independent PRPS isozymes exist in humans, raising the question of whether they serve non-redundant roles.","evidence":"Southern blot analysis of human–mouse somatic cell hybrids and flow-sorted chromosomes","pmids":["2536962"],"confidence":"Medium","gaps":["No functional distinction between isozymes established at this stage","Expression pattern differences not characterized"]},{"year":1992,"claim":"Characterization of the PRPS2 promoter revealed GC-rich architecture with Sp1 sites and cell-type-differential activity, providing the first evidence that PRPS2 expression is transcriptionally regulated.","evidence":"CAT/promoter fusion reporter assays in four cell lines","pmids":["1314091"],"confidence":"Medium","gaps":["Specific transcription factors driving differential expression were not identified","No in vivo promoter validation"]},{"year":2008,"claim":"Identification of PRPS2 as a direct MYC transcriptional target that is rate-limiting for dNTP pools established its integration into the MYC-driven anabolic program and explained why PRPS2 depletion phenocopies MYC loss in proliferating melanoma cells.","evidence":"ChIP for MYC binding at PRPS2, shRNA knockdown, cDNA overexpression, dNTP pool measurements, cell cycle analysis","pmids":["18677108"],"confidence":"High","gaps":["Mechanism by which PRPS2 is selected over PRPS1 by MYC not resolved","Translational versus transcriptional regulation not dissected"]},{"year":2014,"claim":"Demonstration that PRPS2 is translationally upregulated by the Myc→eIF4E axis through a specialized 5′ UTR element—and that Prps2 knockout mice resist Myc-driven tumorigenesis—unified transcriptional and translational control of PRPS2 into a single oncogenic circuit coupling protein synthesis to nucleotide biosynthesis.","evidence":"5′ UTR reporter assays, Prps2 knockout mouse, Myc-transformed cell lines, metabolic assays","pmids":["24855946"],"confidence":"High","gaps":["Identity of RNA-binding proteins or structures within the 5′ UTR that mediate eIF4E sensitivity not defined","Whether PRPS2 loss affects non-Myc oncogene contexts not tested"]},{"year":2015,"claim":"Gain- and loss-of-function experiments in Sertoli cells placed PRPS2 upstream of p53/Bcl-2/caspase apoptosis cascades, revealing a role for PRPS2 in cell survival beyond nucleotide supply.","evidence":"Lentiviral overexpression and knockdown in TM4 Sertoli cells, flow cytometry for apoptosis and cell cycle","pmids":["26004865"],"confidence":"Medium","gaps":["Whether the anti-apoptotic effect is enzymatic or enzyme-independent not determined","Single cell type, not confirmed in vivo"]},{"year":2019,"claim":"Linking PRPS2 to MMP-9 activation and E-cadherin downregulation in colorectal cancer cells extended its oncogenic role from proliferation to invasion and metastasis.","evidence":"PRM-targeted proteomics, migration/invasion assays, MMP-9 activity assay, siRNA knockdown","pmids":["30908912"],"confidence":"Medium","gaps":["Molecular mechanism connecting PRPS2 to MMP-9/E-cadherin regulation not elucidated","Single lab, no in vivo validation of metastasis phenotype"]},{"year":2020,"claim":"In vivo PRPS2 knockdown in mouse testes causing hypospermatogenesis and spermatogenic apoptosis through E2F1 established a physiological role for PRPS2 in male germline maintenance beyond cancer.","evidence":"In vivo testicular knockdown, spermatogenic cell apoptosis quantification, E2F1 target gene analysis","pmids":["31736475"],"confidence":"Medium","gaps":["Whether the fertility phenotype reflects nucleotide depletion or a non-catalytic function is unclear","Full knockout fertility phenotype not reported"]},{"year":2022,"claim":"Discovery that relapse-specific PRPS2 mutations in childhood ALL disrupt hexamer interfaces and reduce ADP/GDP feedback inhibition explained a clinical mechanism of thiopurine resistance and showed that allosteric regulation of PRPS2 is pharmacologically relevant.","evidence":"Ultra-deep sequencing of relapse ALL, in vitro enzyme activity and feedback inhibition assays, UPLC-MS/MS metabolomics, xenograft models","pmids":["36742181"],"confidence":"High","gaps":["Crystal structures of mutant PRPS2 hexamers not determined","Whether combination targeting of PRPS1 and PRPS2 can overcome resistance not tested"]},{"year":2023,"claim":"The 3.08 Å cryo-EM structure of PRPS2 hexamer polymers and mutagenesis of inter-hexamer contacts demonstrated that polymerization is required for full catalytic activity and defined ADP inhibition at atomic resolution, providing the first structural framework for PRPS2 regulation.","evidence":"Cryo-EM at 3.08 Å, site-directed mutagenesis, in vitro polymerization and activity assays","pmids":["37248548"],"confidence":"High","gaps":["Structure of the full heteromeric PRPS complex with PRPSAP1/PRPSAP2 not resolved","In-cell polymer dynamics not observed"]},{"year":2024,"claim":"Combinatorial genetic dissection of the PRPS complex showed that PRPS2, PRPSAP1, and PRPSAP2 are all required for proper PRPS1 assembly, establishing PRPS2 as an obligate component of the functional heteromeric complex rather than a redundant isozyme.","evidence":"Isogenic fibroblast knockout clones (individual and combinatorial), co-fractionation, metabolic flux analysis (preprint)","pmids":["bio_10.1101_2024.10.01.616059"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Stoichiometry of subunits in the native complex not determined","Whether complex composition varies across tissues not explored"]},{"year":2024,"claim":"Identification of CCL2 as a PRPS2-regulated chemokine that recruits TAMs and MDSCs in lung cancer extended PRPS2's oncogenic role to immune evasion and tumor microenvironment remodeling.","evidence":"In vivo LLC tumor models, FACS immune profiling, transwell chemotaxis, CCL2 neutralizing antibody rescue","pmids":["38952044"],"confidence":"Medium","gaps":["Whether the CCL2 effect depends on PRPS2 enzymatic activity or is enzyme-independent not addressed","Human tumor validation lacking"]},{"year":2025,"claim":"Discovery that PRPS2 directly binds and stabilizes MAT2A to drive SAM synthesis and m6A RNA methylation—independent of its PRPP-synthesizing activity—established the first non-catalytic scaffolding function of PRPS2 and explained four non-conserved residues that bypass allosteric feedback inhibition to sustain oncogenic ATP production.","evidence":"Co-IP, protein stability assays, mutational analysis of allosteric sites, m6A methylation assays, in vivo tumorigenesis assays","pmids":["40295500"],"confidence":"High","gaps":["Structural basis of the PRPS2–MAT2A interaction not resolved","Whether enzyme-independent functions extend to other metabolic enzymes not explored"]},{"year":2025,"claim":"Transcriptional repression of PRPS2 by YBX1-mediated displacement of c-Myc and recruitment of the NuRD corepressor complex revealed a druggable upstream node for PRPS2 suppression in triple-negative breast cancer.","evidence":"PRPS2-promoter luciferase, ChIP, biotin-conjugated pull-down, murine metastasis model","pmids":["41855762"],"confidence":"Medium","gaps":["Relevance beyond TNBC not tested","Whether YBX1-mediated repression operates in normal tissues not examined"]},{"year":null,"claim":"Key unresolved questions include the structure of the native heteromeric PRPS1/PRPS2/PRPSAP1/PRPSAP2 complex, the tissue-specific balance between PRPS2 catalytic and non-catalytic functions, whether PRPS2-selective inhibitors can be developed as anti-cancer agents, and how PRPS2's redox regulatory role intersects with its nucleotide biosynthetic and scaffolding activities.","evidence":"","pmids":[],"confidence":"Low","gaps":["No selective PRPS2 inhibitor reported","Structural basis of PRPS2–MAT2A interaction unknown","In vivo dissection of catalytic versus non-catalytic functions not performed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,3,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,12]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,3,4]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,9]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[4]}],"complexes":["PRPS heteromeric complex (PRPS1/PRPS2/PRPSAP1/PRPSAP2)"],"partners":["PRPS1","PRPSAP1","PRPSAP2","MAT2A","MYC","EIF4E","YBX1"],"other_free_text":[]},"mechanistic_narrative":"PRPS2 is an X-linked phosphoribosyl pyrophosphate synthetase that couples nucleotide biosynthesis to oncogenic signaling and redox homeostasis. It catalyzes PRPP synthesis within a heteromeric complex containing PRPS1, PRPSAP1, and PRPSAP2, where PRPS2 is required for proper PRPS1 assembly and maximal metabolic flux; its hexamers stack into higher-order polymers that are essential for full catalytic activity and are inhibited by ADP binding at both allosteric and active sites [PMID:37248548, PMID:36742181]. PRPS2 is transcriptionally activated by c-Myc and translationally upregulated via an eIF4E-responsive 5′ UTR element, making it a rate-limiting node for Myc-driven tumorigenesis; a Prps2 knockout mouse is viable but resistant to Myc-induced lymphomagenesis [PMID:24855946, PMID:18677108]. Beyond its enzymatic role, PRPS2 has an enzyme-independent function in stabilizing MAT2A to drive SAM synthesis and RNA m6A methylation, and it regulates NADPH/NADP⁺ redox balance in MYC-driven lymphoma, tumor immune microenvironment remodeling via CCL2-dependent macrophage/MDSC recruitment, and invasion through MMP-9/E-cadherin [PMID:40295500, PMID:38952044, PMID:30908912]."},"prefetch_data":{"uniprot":{"accession":"P11908","full_name":"Ribose-phosphate pyrophosphokinase 2","aliases":["PPRibP","Phosphoribosyl pyrophosphate synthase II","PRS-II"],"length_aa":318,"mass_kda":34.8,"function":"Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P11908/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRPS2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"PRPF4B","stoichiometry":0.2},{"gene":"SNRPB","stoichiometry":0.2},{"gene":"TOP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRPS2","total_profiled":1310},"omim":[{"mim_id":"603762","title":"PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE-ASSOCIATED PROTEIN 2; PRPSAP2","url":"https://www.omim.org/entry/603762"},{"mim_id":"601249","title":"PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE-ASSOCIATED PROTEIN 1; PRPSAP1","url":"https://www.omim.org/entry/601249"},{"mim_id":"311860","title":"PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE II; PRPS2","url":"https://www.omim.org/entry/311860"},{"mim_id":"311850","title":"PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE I; PRPS1","url":"https://www.omim.org/entry/311850"},{"mim_id":"300661","title":"PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY","url":"https://www.omim.org/entry/300661"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nuclear speckles","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"ovary","ntpm":141.8},{"tissue":"parathyroid gland","ntpm":171.4}],"url":"https://www.proteinatlas.org/search/PRPS2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P11908","domains":[{"cath_id":"3.40.50.2020","chopping":"3-145","consensus_level":"high","plddt":97.1723,"start":3,"end":145},{"cath_id":"3.40.50.2020","chopping":"147-195_205-290","consensus_level":"high","plddt":96.5215,"start":147,"end":290}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11908","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11908-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11908-F1-predicted_aligned_error_v6.png","plddt_mean":95.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRPS2","jax_strain_url":"https://www.jax.org/strain/search?query=PRPS2"},"sequence":{"accession":"P11908","fasta_url":"https://rest.uniprot.org/uniprotkb/P11908.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11908/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11908"}},"corpus_meta":[{"pmid":"24855946","id":"PMC_24855946","title":"Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/24855946","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2536962","id":"PMC_2536962","title":"Localization of human phosphoribosylpyrophosphate synthetase subunit I and II genes (PRPS1 and PRPS2) to different regions of the X chromosome and assignment of two PRPS1-related genes to autosomes.","date":"1989","source":"Somatic cell and molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2536962","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1962753","id":"PMC_1962753","title":"Cloning of cDNAs for human phosphoribosylpyrophosphate synthetases 1 and 2 and X chromosome localization of PRPS1 and PRPS2 genes.","date":"1990","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1962753","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26004865","id":"PMC_26004865","title":"PRPS2 Expression Correlates with Sertoli-Cell Only Syndrome and Inhibits the Apoptosis of TM4 Sertoli Cells.","date":"2015","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/26004865","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37248548","id":"PMC_37248548","title":"Structural basis of human PRPS2 filaments.","date":"2023","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/37248548","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1314091","id":"PMC_1314091","title":"Promoter regions of the human X-linked housekeeping genes PRPS1 and PRPS2 encoding phosphoribosylpyrophosphate synthetase subunit I and II isoforms.","date":"1992","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/1314091","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34251965","id":"PMC_34251965","title":"PRPS2 Enhances Resistance to Cisplatin via Facilitating Exosomes-mediated Macrophage M2 Polarization in Non-small Cell Lung Cancer.","date":"2021","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/34251965","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30908912","id":"PMC_30908912","title":"Targeted Quantitative Kinome Analysis Identifies PRPS2 as a Promoter for Colorectal Cancer Metastasis.","date":"2019","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/30908912","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31736475","id":"PMC_31736475","title":"Phosphoribosyl-pyrophosphate synthetase 2 (PRPS2) depletion regulates spermatogenic cell apoptosis and is correlated with hypospermatogenesis.","date":"2020","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/31736475","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40295500","id":"PMC_40295500","title":"PRPS2 enhances RNA m6A methylation by stimulating SAM synthesis through enzyme-dependent and independent mechanisms.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40295500","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36742181","id":"PMC_36742181","title":"PRPS2 mutations drive acute lymphoblastic leukemia relapse through influencing PRPS1/2 hexamer stability.","date":"2022","source":"Blood science (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36742181","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38952044","id":"PMC_38952044","title":"PRPS2-mediated modulation of the antitumor immune response in lung cancer through CCL2-mediated tumor-associated macrophages and myeloid-derived suppressor cells.","date":"2024","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38952044","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7849396","id":"PMC_7849396","title":"Linkage of phosphoribosylpyrophosphate synthetases 1 and 2, Prps1 and Prps2, on the mouse X chromosome.","date":"1994","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/7849396","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39631276","id":"PMC_39631276","title":"Host protein PRPS2 interact with the non-structural protein p17 of Avian Reovirus and promote viral replication.","date":"2024","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/39631276","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41878508","id":"PMC_41878508","title":"MtfA, a C2H2 transcriptional regulator, negatively regulates PRPS2-mediated biosynthesis of the adenosine analogue acadesine in Fusarium solani.","date":"2025","source":"Mycology","url":"https://pubmed.ncbi.nlm.nih.gov/41878508","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41855762","id":"PMC_41855762","title":"Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple- negative breast cancer.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41855762","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.08.632009","title":"PRPS activity tunes redox homeostasis in Myc-driven lymphoma","date":"2025-01-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.08.632009","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.01.616059","title":"Evolutionary origins and innovations sculpting the mammalian PRPS enzyme complex","date":"2024-10-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.01.616059","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27342126","id":"PMC_27342126","title":"Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27342126","citation_count":306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18677108","id":"PMC_18677108","title":"Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18677108","citation_count":212,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27173435","id":"PMC_27173435","title":"An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27173435","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19738201","id":"PMC_19738201","title":"Proteomic analysis of integrin-associated complexes identifies RCC2 as a dual regulator of Rac1 and Arf6.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19738201","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26990986","id":"PMC_26990986","title":"Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26990986","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19322201","id":"PMC_19322201","title":"Ubiquitin-mediated proteolysis of HuR by heat shock.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19322201","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23891004","id":"PMC_23891004","title":"Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23891004","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"36217030","id":"PMC_36217030","title":"A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36217030","citation_count":140,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30425250","id":"PMC_30425250","title":"Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30425250","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35013556","id":"PMC_35013556","title":"The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35013556","citation_count":122,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34857952","id":"PMC_34857952","title":"Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34857952","citation_count":116,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10176,"output_tokens":3243,"usd":0.039586},"stage2":{"model":"claude-opus-4-6","input_tokens":6596,"output_tokens":2726,"usd":0.151695},"total_usd":0.443093,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":22185,"output_tokens":4564,"usd":0.067507},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8259,"output_tokens":3263,"usd":0.184305}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"PRPS2 is a rate-limiting enzyme for nucleotide biosynthesis in Myc-transformed cells, and its translation is controlled by a specialized cis-regulatory element in the Prps2 5' UTR downstream of eIF4E, which is activated by Myc. A Prps2 knockout mouse demonstrated that PRPS2 is essential for Myc-driven tumorigenesis, coupling protein and nucleotide biosynthesis.\",\n      \"method\": \"5' UTR cis-regulatory element analysis, eIF4E-dependent translation assay, Prps2 knockout mouse model, tumor formation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including knockout mouse, mechanistic translation assays, and functional tumorigenesis readouts in a highly-cited foundational paper\",\n      \"pmids\": [\"24855946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Human PRPS2 forms polymeric filaments (cytoophidia) by stacking hexamers in the presence of ADP at both the canonical allosteric site and the catalytic active site. A point mutation disrupting inter-hexamer interactions prevents PRPS2 polymerization and significantly reduces catalytic activity, establishing that polymer formation is required for full enzymatic function.\",\n      \"method\": \"Cryo-electron microscopy at 3.08 Å resolution, point mutagenesis, enzymatic activity assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure combined with mutagenesis and functional enzyme activity validation\",\n      \"pmids\": [\"37248548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRPS2 uses four non-conserved key residues to bypass ADP/GDP allosteric feedback inhibition, enabling sustained excess ATP production. PRPS2 also stabilizes methionine adenosyltransferase 2A (MAT2A) through direct protein-protein interactions, stimulating SAM synthesis and RNA m6A methylation via the WTAP/METTL3/METTL14 complex, thereby promoting lung tumorigenesis through both enzyme-dependent and enzyme-independent mechanisms.\",\n      \"method\": \"Co-immunoprecipitation, in vitro enzyme activity assays, mutagenesis of non-conserved residues, m6A methylation assays, MAT2A stability assays, lung cancer models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including biochemical reconstitution, mutagenesis, co-IP, and functional cancer models in a single rigorous study\",\n      \"pmids\": [\"40295500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRPS2 mutations in relapsed childhood ALL affect PRPS1/2 hexamer stability, leading to reduced nucleotide feedback inhibition of PRPS enzyme activity and enhanced thiopurine resistance. A 3-amino acid insertion (V103-G104-E105) unique to PRPS2 causes steric clash at the hexamer interface, resulting in low enzyme activity. Mutant PRPS2 (P173R) increased thiopurine resistance in xenograft models.\",\n      \"method\": \"Ultra-deep sequencing, in vitro PRPS2 enzyme activity assay, ADP/GDP feedback inhibition assay, UPLC-MS/MS metabolite analysis, xenograft models\",\n      \"journal\": \"Blood science (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical enzyme assays, structural reasoning with mutagenesis, and in vivo xenograft validation with multiple orthogonal methods\",\n      \"pmids\": [\"36742181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRPS2 promotes migration and invasion of colorectal cancer cells by regulating MMP-9 activity and E-cadherin expression, and its upregulation in metastatic CRC cells is induced by the MYC proto-oncogene.\",\n      \"method\": \"Targeted quantitative proteomics (PRM), cell migration/invasion assays, MMP-9 activity measurement, E-cadherin expression analysis, MYC manipulation\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional knockdown/overexpression with defined cellular phenotype but pathway placement relies on indirect readouts\",\n      \"pmids\": [\"30908912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRPS2 overexpression inhibits apoptosis of TM4 Sertoli cells via the p53/Bcl-2/caspase-9/caspase-3/caspase-6/caspase-7 signaling pathway, and PRPS2 knockdown promotes apoptosis and cell cycle arrest.\",\n      \"method\": \"Lentivirus-mediated overexpression and knockdown, flow cytometry for apoptosis and cell cycle, Western blot for pathway components\",\n      \"journal\": \"The Journal of urology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — clean gain- and loss-of-function with defined pathway readout but no direct biochemical mechanism established\",\n      \"pmids\": [\"26004865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRPS2 depletion in mouse testes causes hypospermatogenesis and accelerated spermatogenic cell apoptosis. E2F1 was identified as a target gene of PRPS2 that regulates apoptosis through the P53/Bcl-xl/Bcl-2/Caspase 6/Caspase 9 pathway.\",\n      \"method\": \"In vivo PRPS2 knockdown in mouse testes, flow cytometry for apoptosis, identification of E2F1 as target gene, apoptosis pathway Western blot\",\n      \"journal\": \"Asian journal of andrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo knockdown with defined phenotype and pathway placement, but E2F1 target identification method not fully detailed\",\n      \"pmids\": [\"31736475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRPS2-containing exosomes secreted by NSCLC cells induce M2 macrophage polarization, and this exosomal PRPS2 promotes cisplatin resistance in NSCLC cells.\",\n      \"method\": \"Exosome isolation by ultracentrifugation, siRNA silencing, macrophage polarization assays, MTT and colony formation assays, caspase-3 activity assay\",\n      \"journal\": \"Immunological investigations\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mechanism of exosomal PRPS2-driven M2 polarization not biochemically resolved\",\n      \"pmids\": [\"34251965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRPS2 regulates chemotaxis of tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) in lung cancer by mediating CCL2 expression. Knockdown of CCL2 reversed the immune-suppressive phenotype induced by PRPS2 overexpression in vivo.\",\n      \"method\": \"Lentivirus stable cell lines, in vitro transwell chemotaxis assay, flow cytometry for immune cell populations, in vivo LLC tumor models, ELISA, qPCR, Western blot\",\n      \"journal\": \"Thoracic cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo and in vitro evidence with CCL2 epistasis, though the biochemical link between PRPS2 and CCL2 expression is not fully resolved\",\n      \"pmids\": [\"38952044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Genetic inactivation of PRPS2 (but not PRPS1) in MYC-driven lymphoma cells leads to elevated NADPH levels and reductive stress-mediated death, identifying PRPS2 as a primary regulator of redox status in lymphoma. Targeting PRPS1 or PRPS2 elicits opposing sensitivity or resistance to chemotherapeutic agents affecting the thioredoxin and glutathione network.\",\n      \"method\": \"Genetic inactivation (isozyme-specific knockout), NADPH measurement, pharmacological screen, chemotherapeutic sensitivity assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isozyme-specific genetic inactivation with defined metabolic and cell death phenotype, preprint without peer review\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The mammalian PRPS enzyme operates as a large molecular weight complex with heterogeneous multimeric configurations. PRPS2 preferentially interacts with PRPSAP1 and PRPSAP2 (non-enzymatic associated proteins), and cells lacking PRPS2, PRPSAP1, and PRPSAP2 render PRPS1 into aberrant homo-oligomeric assemblies with diminished metabolic flux and impaired proliferative capacity. Translational control mechanisms enable fine-tuned regulation of PRPS complex assembly.\",\n      \"method\": \"Isogenic fibroblast knockout clones in individual and combinatorial assembly states, co-immunoprecipitation, metabolic flux analysis, proliferation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple isogenic knockout combinations with biochemical and functional readouts, preprint without peer review\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The PRPS2 gene promoter is GC-rich, contains a TATA-like sequence, four Sp1 binding sites, and a homopyrimidine stretch, with transcription initiation sites 90 nt upstream of ATG. CAT/promoter fusion assays showed that a 1.1 kb 5' flanking region drives cell-differential PRPS2 expression.\",\n      \"method\": \"Promoter-CAT fusion reporter assay, transcription initiation mapping\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct reporter assay establishing functional promoter elements\",\n      \"pmids\": [\"1314091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"The transcription factor YBX1 binds the PRPS2 promoter and competes with the transcriptional activator c-Myc. YBX1 recruits the NuRD corepressor complex to the PRPS2 promoter, leading to transcriptional repression of PRPS2.\",\n      \"method\": \"PRPS2-promoter-driven luciferase reporter assay, biotin-conjugated pull-down, chromatin immunoprecipitation (ChIP), reporter assays\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and pull-down assays establishing direct promoter binding and corepressor recruitment, but single lab study\",\n      \"pmids\": [\"41855762\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRPS2 is a rate-limiting phosphoribosyl pyrophosphate synthetase that forms regulated multimeric complexes (hexamers and filaments) with PRPS1 and non-enzymatic associated proteins; its translation is controlled by a Myc/eIF4E-dependent 5' UTR element, it bypasses ADP/GDP allosteric inhibition via non-conserved residues to sustain ATP and nucleotide production, directly stabilizes MAT2A to promote SAM synthesis and RNA m6A methylation, regulates cellular redox homeostasis (NADPH levels) in Myc-driven lymphoma, and mediates tumor progression through both enzyme-dependent nucleotide biosynthesis and enzyme-independent protein interactions including CCL2-driven immune modulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"PRPS2 is a rate-limiting enzyme for nucleotide biosynthesis that is specifically upregulated at the translational level downstream of Myc activation via a specialized cis-regulatory element in the PRPS2 5' UTR controlled by the translation initiation factor eIF4E. A Prps2 knockout mouse demonstrated that this Myc→eIF4E→PRPS2 axis is required for Myc-driven tumorigenesis, coupling protein synthesis (via eIF4E) and nucleotide biosynthesis (via PRPS2) in a single anabolic circuit.\",\n      \"method\": \"5' UTR reporter assays, Prps2 knockout mouse, Myc-transformed cell lines, metabolic assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic knockout mouse with defined phenotype, mechanistic 5'UTR reporter assays, multiple orthogonal methods in a single highly-cited study\",\n      \"pmids\": [\"24855946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRPS2 is a direct transcriptional target of C-MYC and is rate-limiting for dNTP metabolism in melanoma cells. shRNA-mediated knockdown of PRPS2 reduced dNTP pools and retarded cell cycle progression similarly to C-MYC depletion; conversely, PRPS2 overexpression (together with TS and IMPDH2) delayed proliferative arrest caused by C-MYC inhibition. ChIP confirmed direct C-MYC binding to the PRPS2 gene.\",\n      \"method\": \"shRNA knockdown, cDNA overexpression, dNTP pool measurements, ChIP, cell cycle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, KD, OE, metabolite measurement) with defined phenotypic readouts\",\n      \"pmids\": [\"18677108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of human PRPS2 at 3.08 Å resolution revealed that hPRPS2 hexamers stack into polymers in the presence of the allosteric/competitive inhibitor ADP. The binding modes of ADP at the canonical allosteric site and at the catalytic active site were determined. A point mutation disrupting inter-hexamer contacts prevents hPRPS2 polymerization and results in significantly reduced catalytic activity, demonstrating that polymer formation regulates enzymatic activity. The regulation of hPRPS2 polymers is distinct from that of E. coli PRPS polymers.\",\n      \"method\": \"Cryo-EM structure determination (3.08 Å), site-directed mutagenesis, in vitro polymerization and activity assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution cryo-EM structure combined with mutagenesis and activity assays\",\n      \"pmids\": [\"37248548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRPS2 mutations found exclusively in relapsed childhood ALL drive thiopurine resistance by influencing PRPS1/PRPS2 hexamer stability. The 3-amino acid insertion V103-G104-E105 in PRPS2 causes steric clash at the hexamer interface, reducing enzyme activity. Functional PRPS2 mutations reduce ADP/GDP feedback inhibition of PRPS enzyme activity, enhancing purine metabolic flux and thiopurine resistance, demonstrated in cell lines and xenograft models.\",\n      \"method\": \"Ultra-deep sequencing, in vitro PRPS2 enzyme activity assays, ADP/GDP feedback inhibition assays, UPLC-MS/MS metabolite profiling, xenograft mouse models\",\n      \"journal\": \"Blood science (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzyme activity assays, metabolomics, and in vivo xenograft validation with mechanistic structural explanation\",\n      \"pmids\": [\"36742181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRPS2 uses four non-conserved key residues to bypass typical ADP/GDP allosteric feedback inhibition, enabling sustained excess ATP production. Additionally, PRPS2 directly interacts with and stabilizes methionine adenosyltransferase 2A (MAT2A) through protein-protein interaction, stimulating SAM synthesis which feeds the WTAP/METTL3/METTL14 methyltransferase complex for RNA m6A methylation, thereby promoting lung tumorigenesis. This reveals both enzyme-dependent (ATP production) and enzyme-independent (MAT2A stabilization) oncogenic functions of PRPS2.\",\n      \"method\": \"Co-immunoprecipitation, protein stability assays, mutational analysis of allosteric sites, m6A methylation assays, in vitro and in vivo tumorigenesis assays, MAT2A interaction studies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (Co-IP, mutagenesis, methylation assays, in vivo tumor models) establishing both enzyme-dependent and independent mechanisms\",\n      \"pmids\": [\"40295500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRPS2 promotes migration and invasion of colorectal cancer cells by regulating the activity of matrix metalloproteinase 9 (MMP-9) and the expression of E-cadherin. Upregulation of PRPS2 in metastatic CRC cells is induced by the MYC proto-oncogene.\",\n      \"method\": \"PRM-based targeted proteomics, migration/invasion assays, MMP-9 activity assays, Western blot, siRNA knockdown\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional assays with defined molecular outputs (MMP-9, E-cadherin) from a single lab\",\n      \"pmids\": [\"30908912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRPS2 overexpression in TM4 Sertoli cells inhibits apoptosis and promotes cell cycle transition via the p53/Bcl-2/caspase-9/caspase-3/caspase-6/caspase-7 signaling pathway, as demonstrated by lentiviral gain- and loss-of-function experiments with flow cytometry readouts.\",\n      \"method\": \"Lentiviral overexpression and knockdown, flow cytometry (apoptosis, cell cycle), Western blot for apoptosis pathway proteins\",\n      \"journal\": \"The Journal of urology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — defined apoptosis pathway placement via gain/loss of function with multiple apoptosis markers, single lab\",\n      \"pmids\": [\"26004865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRPS2 depletion in mouse testes causes hypospermatogenesis and accelerated spermatogenic cell apoptosis. E2F1 transcription factor was identified as a target gene regulated by PRPS2, with E2F1 acting through the P53/Bcl-xl/Bcl-2/Caspase 6/Caspase 9 apoptosis pathway. In vivo knockdown of PRPS2 in mouse testes confirmed the hypospermatogenesis phenotype.\",\n      \"method\": \"In vivo testicular PRPS2 knockdown in mice, spermatogenic cell apoptosis quantification, E2F1 target gene analysis, apoptosis pathway protein assays\",\n      \"journal\": \"Asian journal of andrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — in vivo knockdown with defined phenotype and identification of downstream transcription factor, single lab\",\n      \"pmids\": [\"31736475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRPS2 silencing enhances cisplatin sensitivity in NSCLC cells. PRPS2 is enriched in exosomes secreted by NSCLC cells, and exosomal PRPS2 mediates M2 macrophage polarization, which in turn promotes cisplatin resistance in NSCLC cells.\",\n      \"method\": \"siRNA knockdown, exosome isolation by ultracentrifugation, MTT and colony formation assays, ELISA, caspase-3 activity assay, macrophage polarization assays\",\n      \"journal\": \"Immunological investigations\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional assays with exosome mechanistic link, single lab, no structural or biochemical reconstitution\",\n      \"pmids\": [\"34251965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRPS2 regulates chemotaxis of tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) in lung cancer by controlling CCL2 expression. In vivo LLC tumor models showed that PRPS2 knockdown reduced TAM/MDSC infiltration and increased CD4+/CD8+ T cell percentages; CCL2 antibody treatment reversed the pro-tumorigenic phenotype induced by PRPS2 overexpression.\",\n      \"method\": \"Lentiviral stable cell lines, in vivo mouse tumor models, FACS, in vitro transwell chemotaxis assay, qPCR, Western blot, ELISA\",\n      \"journal\": \"Thoracic cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — in vivo tumor model with multiple immune cell readouts; CCL2 identified as intermediate; single lab\",\n      \"pmids\": [\"38952044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Host PRPS2 directly interacts with Avian Reovirus non-structural protein p17, as validated by yeast two-hybrid, coimmunoprecipitation, GST-pulldown, and laser confocal microscopy. The C-terminal region of PRPS2 is responsible for binding p17. ARV infection upregulates PRPS2, and PRPS2 overexpression increases ARV replication while knockdown decreases it, with cellular apoptosis implicated as a mechanism.\",\n      \"method\": \"Yeast two-hybrid, coimmunoprecipitation, GST-pulldown, laser confocal microscopy, overexpression and knockdown in avian cells\",\n      \"journal\": \"Poultry science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — interaction validated by multiple orthogonal methods; functional consequence shown by gain/loss of function; avian host context\",\n      \"pmids\": [\"39631276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Genetic inactivation of the PRPS2 isozyme (but not PRPS1) in MYC-driven lymphoma cells leads to elevated NADPH levels and reductive stress-mediated cell death, identifying PRPS2 as a primary regulator of redox homeostasis in Myc-overexpressing B cell lymphomas. MYC overexpression rapidly stimulates PRPS2-dependent nucleotide synthesis and modulates the pentose phosphate pathway and mitochondrial respiration to shift redox equilibrium toward a more oxidative state. Pharmacological targeting of PRPS1 versus PRPS2 elicits opposing sensitivity or resistance to thioredoxin/glutathione network-targeting chemotherapeutics.\",\n      \"method\": \"Genetic isozyme-specific inactivation (PRPS2 KO vs PRPS1 KO), NADPH measurements, pharmacological screen, redox assays in MYC-overexpressing B cell lymphoma cells\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isozyme-specific genetic inactivation with metabolic readouts; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.01.08.632009\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRPS2 operates as part of a large mammalian PRPS enzyme complex together with PRPS1, PRPS3 (testis-restricted), and two non-enzymatic associated proteins (PRPSAP1, PRPSAP2). PRPS2, PRPSAP1, and PRPSAP2 are required for proper PRPS1 assembly; cells lacking all three render PRPS1 into aberrant homo-oligomeric assemblies with diminished metabolic flux and impaired proliferative capacity. Preferential interactions between complex subunits were defined using isogenic fibroblast clones in all viable individual or combinatorial assembly states. Translational control mechanisms enable fine-tuned regulation of PRPS complex assembly.\",\n      \"method\": \"Isogenic fibroblast knockout clones (individual and combinatorial), co-fractionation, affinity purification, metabolic flux analysis, proliferation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive combinatorial genetic approach with metabolic and proliferative readouts; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.10.01.616059\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The PRPS2 gene was localized to the X chromosome at a different region than PRPS1, specifically Xpter-q21, using Southern blot analysis of human-mouse somatic cell hybrids and flow-sorted human chromosomes, demonstrating that PRPS1 and PRPS2 are encoded by distinct, separated loci on the X chromosome.\",\n      \"method\": \"Southern blot analysis of somatic cell hybrids, flow-sorted chromosome hybridization\",\n      \"journal\": \"Somatic cell and molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — definitive chromosomal mapping by molecular genetics\",\n      \"pmids\": [\"2536962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The PRPS2 gene promoter region is GC-rich, contains a TATA-like sequence, four Sp1 binding sites, and a homopyrimidine stretch, with transcription initiation sites 90 nucleotides upstream from the ATG codon. CAT/promoter fusion assays in four cell lines demonstrated that a 1.1 kb PRPS2 5'-flanking region possesses promoter activity correlated with steady-state PRPS2 mRNA levels, suggesting this region drives cell-differential expression.\",\n      \"method\": \"Promoter cloning, sequencing, CAT/promoter fusion reporter assays in multiple cell lines\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter activity demonstrated by reporter assays in multiple cell lines\",\n      \"pmids\": [\"1314091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Pseudoginsenoside F11 (PF11) inhibits PRPS2 transcription by binding to the transcription factor YBX1, enhancing its affinity for the PRPS2 promoter and enabling displacement of the transcriptional activator c-Myc. YBX1 then recruits the NuRD corepressor complex to the PRPS2 promoter, leading to transcriptional repression of PRPS2, suppression of TNBC stemness, and reduction of pulmonary metastasis in murine models.\",\n      \"method\": \"PRPS2-promoter luciferase reporter assay, biotin-conjugated pull-down, ChIP, YBX1 knockdown/overexpression, in vitro mammosphere assay, murine pulmonary metastasis model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — mechanistic promoter studies with ChIP and pull-down; in vivo validation; single lab\",\n      \"pmids\": [\"41855762\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRPS2 is an X-linked phosphoribosyl pyrophosphate synthetase that catalyzes the rate-limiting step of nucleotide biosynthesis; it forms hexamers that stack into higher-order polymers (whose structure and ADP-inhibited state are defined at atomic resolution), assembles into a large heteromeric complex with PRPS1, PRPSAP1, and PRPSAP2, and is selectively upregulated at the translational level by the Myc→eIF4E axis via a specialized 5'UTR element; beyond its enzymatic role in ATP/PRPP production, PRPS2 independently stabilizes MAT2A to drive SAM synthesis and RNA m6A methylation, regulates redox homeostasis (NADPH/NADP+ balance) in MYC-driven lymphoma, modulates apoptosis through p53/Bcl-2/caspase cascades and E2F1, and promotes tumor invasion via MMP-9/E-cadherin regulation and immune evasion via CCL2-mediated macrophage/MDSC recruitment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRPS2 is a phosphoribosyl pyrophosphate synthetase isoform that functions as a regulated nexus coupling nucleotide biosynthesis, methionine metabolism, and redox homeostasis to oncogenic signaling. Its translation is controlled by a specialized 5′ UTR cis-regulatory element activated by Myc via eIF4E, making it a rate-limiting enzyme for nucleotide production in Myc-driven tumors, as demonstrated by the essential requirement for PRPS2 in Myc-dependent tumorigenesis in knockout mice [PMID:24855946]. PRPS2 assembles into catalytically active polymeric filaments through ADP-dependent hexamer stacking, and four non-conserved residues enable it to bypass ADP/GDP allosteric feedback inhibition, sustaining excess ATP production; additionally, PRPS2 directly stabilizes MAT2A to promote SAM synthesis and RNA m6A methylation via the WTAP/METTL3/METTL14 complex, linking nucleotide metabolism to the epitranscriptome [PMID:37248548, PMID:40295500]. PRPS2 also modulates the tumor immune microenvironment by driving CCL2-dependent recruitment of immunosuppressive myeloid cells [PMID:38952044].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Characterization of the PRPS2 promoter established that its transcription is driven by a GC-rich, Sp1-site-containing regulatory region that confers cell-type-differential expression, providing the first insight into how PRPS2 expression is controlled at the transcriptional level.\",\n      \"evidence\": \"Promoter-CAT fusion reporter assays with a 1.1 kb 5′ flanking region and transcription initiation mapping\",\n      \"pmids\": [\"1314091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signaling inputs to the promoter were not defined\", \"Post-transcriptional regulation was not addressed\", \"In vivo relevance of promoter elements was not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The discovery that PRPS2 translation is selectively activated by a Myc/eIF4E-dependent 5′ UTR element, and that PRPS2 is essential for Myc-driven tumorigenesis in knockout mice, established PRPS2 as the rate-limiting isoform coupling protein synthesis capacity to nucleotide biosynthesis in cancer.\",\n      \"evidence\": \"5′ UTR cis-element dissection, eIF4E-dependent translation assays, Prps2 knockout mouse, tumor formation assays in Myc-transformed cells\",\n      \"pmids\": [\"24855946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for translational selectivity of the 5′ UTR was not resolved\", \"Whether PRPS2 has functions beyond nucleotide biosynthesis in Myc-driven contexts was unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Gain- and loss-of-function experiments in Sertoli cells showed PRPS2 inhibits apoptosis via the p53/Bcl-2/caspase pathway, revealing a pro-survival role for PRPS2 outside of oncogenic contexts.\",\n      \"evidence\": \"Lentiviral overexpression and knockdown in TM4 Sertoli cells, flow cytometry, Western blot for apoptosis markers\",\n      \"pmids\": [\"26004865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct biochemical mechanism linking PRPS2 enzymatic activity to apoptosis suppression was identified\", \"Relevance to spermatogenesis in vivo was not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"In vivo PRPS2 knockdown in mouse testes demonstrated that PRPS2 is required for normal spermatogenesis and that its loss causes accelerated germ cell apoptosis through E2F1 and the p53/caspase axis, extending the pro-survival role to a physiological tissue context.\",\n      \"evidence\": \"In vivo testicular PRPS2 knockdown in mice, apoptosis quantification, identification of E2F1 as downstream target\",\n      \"pmids\": [\"31736475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How PRPS2 regulates E2F1 expression was not biochemically resolved\", \"Whether the apoptosis phenotype reflects nucleotide depletion or a non-enzymatic function was not distinguished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Structural and biochemical analysis of PRPS2 mutations in relapsed childhood ALL revealed that a 3-amino-acid insertion unique to PRPS2 creates steric clash at the hexamer interface reducing activity, and that specific mutations (P173R) reduce nucleotide feedback inhibition to confer thiopurine resistance.\",\n      \"evidence\": \"Ultra-deep sequencing of relapsed ALL samples, in vitro enzyme activity and ADP/GDP inhibition assays, UPLC-MS/MS metabolomics, xenograft validation\",\n      \"pmids\": [\"36742181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic-resolution structure of mutant PRPS2 hexamers was not determined\", \"Whether PRPS2 mutations arise under selective pressure of therapy versus pre-exist was not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM resolved that PRPS2 forms catalytically essential polymeric filaments (cytoophidia) by ADP-dependent hexamer stacking, and mutagenesis demonstrated that disruption of inter-hexamer contacts abolishes both polymerization and full catalytic activity.\",\n      \"evidence\": \"3.08 Å cryo-EM structure, point mutagenesis of inter-hexamer interface, enzymatic activity assays\",\n      \"pmids\": [\"37248548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological triggers for filament assembly and disassembly in cells were not identified\", \"Whether PRPS1–PRPS2 mixed filaments form and their functional significance was not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PRPS2 was shown to drive immunosuppressive tumor microenvironment remodeling by promoting CCL2-dependent chemotaxis of tumor-associated macrophages and myeloid-derived suppressor cells, revealing an immune-modulatory axis downstream of PRPS2.\",\n      \"evidence\": \"Lentiviral stable lines, transwell chemotaxis, flow cytometry of immune populations, in vivo LLC tumor models with CCL2 knockdown epistasis\",\n      \"pmids\": [\"38952044\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The biochemical mechanism linking PRPS2 to CCL2 transcription or secretion was not resolved\", \"Whether this immune function depends on PRPS2 enzymatic activity was not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of four non-conserved residues that allow PRPS2 to bypass ADP/GDP allosteric inhibition, and the discovery that PRPS2 directly stabilizes MAT2A to promote SAM synthesis and m6A RNA methylation, established dual enzyme-dependent and enzyme-independent oncogenic mechanisms.\",\n      \"evidence\": \"Co-immunoprecipitation, mutagenesis of non-conserved residues, in vitro enzyme assays, m6A methylation quantification, MAT2A stability assays, lung cancer models\",\n      \"pmids\": [\"40295500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for PRPS2–MAT2A interaction was not determined\", \"Whether MAT2A stabilization occurs in non-tumor contexts was not tested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"The transcription factor YBX1 was identified as a direct repressor of PRPS2 transcription that competes with c-Myc at the PRPS2 promoter and recruits the NuRD corepressor complex, establishing a transcriptional toggle controlling PRPS2 expression.\",\n      \"evidence\": \"ChIP, biotin-conjugated pull-down of PRPS2 promoter-binding proteins, luciferase reporter assays\",\n      \"pmids\": [\"41855762\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo significance of YBX1-mediated PRPS2 repression for tumor phenotypes was not demonstrated\", \"Whether YBX1 repression is context-specific or constitutive was not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The relative contributions of PRPS2's enzymatic (nucleotide biosynthesis, ATP production) versus non-enzymatic (MAT2A stabilization, CCL2 regulation, immune modulation) functions to tumorigenesis remain unresolved, as does the structural basis for PRPS1–PRPS2 heteromeric complex assembly and the signals governing filament dynamics in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No separation-of-function mutants cleanly dissecting enzymatic from scaffolding roles in vivo\", \"Structure of native PRPS1/PRPS2/PRPSAP heteromeric complexes is unresolved\", \"How PRPS2 controls cellular redox (NADPH) independently of PRPS1 awaits peer-reviewed confirmation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 3, 4]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\n      \"PRPS hexamer\",\n      \"PRPS/PRPSAP1/PRPSAP2 complex\"\n    ],\n    \"partners\": [\n      \"PRPS1\",\n      \"PRPSAP1\",\n      \"PRPSAP2\",\n      \"MAT2A\",\n      \"eIF4E\",\n      \"YBX1\",\n      \"MYC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRPS2 is an X-linked phosphoribosyl pyrophosphate synthetase that couples nucleotide biosynthesis to oncogenic signaling and redox homeostasis. It catalyzes PRPP synthesis within a heteromeric complex containing PRPS1, PRPSAP1, and PRPSAP2, where PRPS2 is required for proper PRPS1 assembly and maximal metabolic flux; its hexamers stack into higher-order polymers that are essential for full catalytic activity and are inhibited by ADP binding at both allosteric and active sites [PMID:37248548, PMID:36742181]. PRPS2 is transcriptionally activated by c-Myc and translationally upregulated via an eIF4E-responsive 5′ UTR element, making it a rate-limiting node for Myc-driven tumorigenesis; a Prps2 knockout mouse is viable but resistant to Myc-induced lymphomagenesis [PMID:24855946, PMID:18677108]. Beyond its enzymatic role, PRPS2 has an enzyme-independent function in stabilizing MAT2A to drive SAM synthesis and RNA m6A methylation, and it regulates NADPH/NADP⁺ redox balance in MYC-driven lymphoma, tumor immune microenvironment remodeling via CCL2-dependent macrophage/MDSC recruitment, and invasion through MMP-9/E-cadherin [PMID:40295500, PMID:38952044, PMID:30908912].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Mapping PRPS2 to the X chromosome at a locus distinct from PRPS1 established that two independent PRPS isozymes exist in humans, raising the question of whether they serve non-redundant roles.\",\n      \"evidence\": \"Southern blot analysis of human–mouse somatic cell hybrids and flow-sorted chromosomes\",\n      \"pmids\": [\"2536962\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional distinction between isozymes established at this stage\", \"Expression pattern differences not characterized\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Characterization of the PRPS2 promoter revealed GC-rich architecture with Sp1 sites and cell-type-differential activity, providing the first evidence that PRPS2 expression is transcriptionally regulated.\",\n      \"evidence\": \"CAT/promoter fusion reporter assays in four cell lines\",\n      \"pmids\": [\"1314091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific transcription factors driving differential expression were not identified\", \"No in vivo promoter validation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of PRPS2 as a direct MYC transcriptional target that is rate-limiting for dNTP pools established its integration into the MYC-driven anabolic program and explained why PRPS2 depletion phenocopies MYC loss in proliferating melanoma cells.\",\n      \"evidence\": \"ChIP for MYC binding at PRPS2, shRNA knockdown, cDNA overexpression, dNTP pool measurements, cell cycle analysis\",\n      \"pmids\": [\"18677108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PRPS2 is selected over PRPS1 by MYC not resolved\", \"Translational versus transcriptional regulation not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstration that PRPS2 is translationally upregulated by the Myc→eIF4E axis through a specialized 5′ UTR element—and that Prps2 knockout mice resist Myc-driven tumorigenesis—unified transcriptional and translational control of PRPS2 into a single oncogenic circuit coupling protein synthesis to nucleotide biosynthesis.\",\n      \"evidence\": \"5′ UTR reporter assays, Prps2 knockout mouse, Myc-transformed cell lines, metabolic assays\",\n      \"pmids\": [\"24855946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of RNA-binding proteins or structures within the 5′ UTR that mediate eIF4E sensitivity not defined\", \"Whether PRPS2 loss affects non-Myc oncogene contexts not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Gain- and loss-of-function experiments in Sertoli cells placed PRPS2 upstream of p53/Bcl-2/caspase apoptosis cascades, revealing a role for PRPS2 in cell survival beyond nucleotide supply.\",\n      \"evidence\": \"Lentiviral overexpression and knockdown in TM4 Sertoli cells, flow cytometry for apoptosis and cell cycle\",\n      \"pmids\": [\"26004865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the anti-apoptotic effect is enzymatic or enzyme-independent not determined\", \"Single cell type, not confirmed in vivo\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linking PRPS2 to MMP-9 activation and E-cadherin downregulation in colorectal cancer cells extended its oncogenic role from proliferation to invasion and metastasis.\",\n      \"evidence\": \"PRM-targeted proteomics, migration/invasion assays, MMP-9 activity assay, siRNA knockdown\",\n      \"pmids\": [\"30908912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism connecting PRPS2 to MMP-9/E-cadherin regulation not elucidated\", \"Single lab, no in vivo validation of metastasis phenotype\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"In vivo PRPS2 knockdown in mouse testes causing hypospermatogenesis and spermatogenic apoptosis through E2F1 established a physiological role for PRPS2 in male germline maintenance beyond cancer.\",\n      \"evidence\": \"In vivo testicular knockdown, spermatogenic cell apoptosis quantification, E2F1 target gene analysis\",\n      \"pmids\": [\"31736475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the fertility phenotype reflects nucleotide depletion or a non-catalytic function is unclear\", \"Full knockout fertility phenotype not reported\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that relapse-specific PRPS2 mutations in childhood ALL disrupt hexamer interfaces and reduce ADP/GDP feedback inhibition explained a clinical mechanism of thiopurine resistance and showed that allosteric regulation of PRPS2 is pharmacologically relevant.\",\n      \"evidence\": \"Ultra-deep sequencing of relapse ALL, in vitro enzyme activity and feedback inhibition assays, UPLC-MS/MS metabolomics, xenograft models\",\n      \"pmids\": [\"36742181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structures of mutant PRPS2 hexamers not determined\", \"Whether combination targeting of PRPS1 and PRPS2 can overcome resistance not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The 3.08 Å cryo-EM structure of PRPS2 hexamer polymers and mutagenesis of inter-hexamer contacts demonstrated that polymerization is required for full catalytic activity and defined ADP inhibition at atomic resolution, providing the first structural framework for PRPS2 regulation.\",\n      \"evidence\": \"Cryo-EM at 3.08 Å, site-directed mutagenesis, in vitro polymerization and activity assays\",\n      \"pmids\": [\"37248548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full heteromeric PRPS complex with PRPSAP1/PRPSAP2 not resolved\", \"In-cell polymer dynamics not observed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Combinatorial genetic dissection of the PRPS complex showed that PRPS2, PRPSAP1, and PRPSAP2 are all required for proper PRPS1 assembly, establishing PRPS2 as an obligate component of the functional heteromeric complex rather than a redundant isozyme.\",\n      \"evidence\": \"Isogenic fibroblast knockout clones (individual and combinatorial), co-fractionation, metabolic flux analysis (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.10.01.616059\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Stoichiometry of subunits in the native complex not determined\", \"Whether complex composition varies across tissues not explored\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of CCL2 as a PRPS2-regulated chemokine that recruits TAMs and MDSCs in lung cancer extended PRPS2's oncogenic role to immune evasion and tumor microenvironment remodeling.\",\n      \"evidence\": \"In vivo LLC tumor models, FACS immune profiling, transwell chemotaxis, CCL2 neutralizing antibody rescue\",\n      \"pmids\": [\"38952044\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the CCL2 effect depends on PRPS2 enzymatic activity or is enzyme-independent not addressed\", \"Human tumor validation lacking\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that PRPS2 directly binds and stabilizes MAT2A to drive SAM synthesis and m6A RNA methylation—independent of its PRPP-synthesizing activity—established the first non-catalytic scaffolding function of PRPS2 and explained four non-conserved residues that bypass allosteric feedback inhibition to sustain oncogenic ATP production.\",\n      \"evidence\": \"Co-IP, protein stability assays, mutational analysis of allosteric sites, m6A methylation assays, in vivo tumorigenesis assays\",\n      \"pmids\": [\"40295500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the PRPS2–MAT2A interaction not resolved\", \"Whether enzyme-independent functions extend to other metabolic enzymes not explored\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Transcriptional repression of PRPS2 by YBX1-mediated displacement of c-Myc and recruitment of the NuRD corepressor complex revealed a druggable upstream node for PRPS2 suppression in triple-negative breast cancer.\",\n      \"evidence\": \"PRPS2-promoter luciferase, ChIP, biotin-conjugated pull-down, murine metastasis model\",\n      \"pmids\": [\"41855762\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevance beyond TNBC not tested\", \"Whether YBX1-mediated repression operates in normal tissues not examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structure of the native heteromeric PRPS1/PRPS2/PRPSAP1/PRPSAP2 complex, the tissue-specific balance between PRPS2 catalytic and non-catalytic functions, whether PRPS2-selective inhibitors can be developed as anti-cancer agents, and how PRPS2's redox regulatory role intersects with its nucleotide biosynthetic and scaffolding activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No selective PRPS2 inhibitor reported\", \"Structural basis of PRPS2–MAT2A interaction unknown\", \"In vivo dissection of catalytic versus non-catalytic functions not performed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 3, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 3, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 9]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [\n      \"PRPS heteromeric complex (PRPS1/PRPS2/PRPSAP1/PRPSAP2)\"\n    ],\n    \"partners\": [\n      \"PRPS1\",\n      \"PRPSAP1\",\n      \"PRPSAP2\",\n      \"MAT2A\",\n      \"MYC\",\n      \"eIF4E\",\n      \"YBX1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}